Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group
- PMID: 10398181
- DOI: 10.1002/(sici)1096-911x(199908)33:2<83::aid-mpo4>3.0.co;2-g
Regimen-related toxicity of myeloablative chemotherapy with BCNU, thiotepa, and etoposide followed by autologous stem cell rescue for children with newly diagnosed glioblastoma multiforme: report from the Children's Cancer Group
Abstract
Background: The survival of children with glioblastoma multiforme (GBM) remains poor. In an effort to improve the cure rate of children with this disease, high-dose chemotherapy followed by autologous stem cell rescue (ASCR) has been evaluated. We report the regimen-related toxicity (RRT) and survival seen in 11 children with newly diagnosed GBM treated with high-dose chemotherapy on a Children's Cancer Group study (CCG-9922).
Procedures: This phase II pilot study, intended to treat 30 patients, accrued 11 patients from July, 1993, to April, 1995. The pre-ASCR preparative regimen included BCNU 100 mg/m2 every 12 hr for a total of six doses on days -8, -7, -6; thiotepa 300 mg/m2/day on days -5, -4, -3; and etoposide 250 mg/m2/day on days -5, -4, -3. All patients received delayed radiotherapy at a dose of 5,400 cGy to the primary site commencing on approximately day +42 after ASCR.
Results: Five patients (45%) developed significant, nonfatal (grade III or IV) pulmonary and/or neurological toxicities. Three patients developed signs and/or symptoms of idiopathic interstitial pneumonitis. Eight patients (73%) have died, two (18%) of toxicity, and six (55%) of disease progression. Three patients (27%) achieved and remain in complete radiographic remission 2.9, 3.9, and 5.1 years from ASCR. One of these three, developed a lymphoblastic non-Hodgkins lymphoma (NHL) 3. 5 years post-ASCR. The survival rates for these 11 children at 1 year and 2 years are 73% +/- 13% and 46% +/- 14%, respectively. The progression-free survival rates at 1 year and at 2 years are 64% +/- 14% and 46% +/- 14%, respectively.
Conclusions: We conclude that high-dose chemotherapeutic regimens followed by ASCR is a feasible treatment of childhood GBM. The BCNU-based preparative regimen utilized in this study was associated with prohibitive pulmonary toxicity.
Copyright 1999 Wiley-Liss, Inc.
Similar articles
-
High-dose multi-agent chemotherapy followed by bone marrow 'rescue' for malignant astrocytomas of childhood and adolescence.J Neurooncol. 1990 Dec;9(3):239-48. doi: 10.1007/BF02341155. J Neurooncol. 1990. PMID: 1964962 Clinical Trial.
-
High dose chemotherapy with autologous bone marrow rescue for children with diffuse pontine brain stem tumors. Children's Cancer Group.J Neurooncol. 1998 Mar;37(1):67-73. doi: 10.1023/a:1005874508975. J Neurooncol. 1998. PMID: 9525840 Clinical Trial.
-
Treatment of newly diagnosed glioblastoma multiforme with carmustine, cisplatin and etoposide followed by radiotherapy. A phase II study.J Neurooncol. 1999 Jun;43(2):161-6. doi: 10.1023/a:1006254716877. J Neurooncol. 1999. PMID: 10533728 Clinical Trial.
-
Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.Cancer Chemother Pharmacol. 2002 May;49 Suppl 1:S13-20. doi: 10.1007/s00280-002-0447-1. Epub 2002 Apr 12. Cancer Chemother Pharmacol. 2002. PMID: 12042984 Review.
-
How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review.J Clin Oncol. 2001 Feb 1;19(3):870-80. doi: 10.1200/JCO.2001.19.3.870. J Clin Oncol. 2001. PMID: 11157041 Review.
Cited by
-
Pediatric glioblastoma multiforme: A single-institution experience.Indian J Med Paediatr Oncol. 2012 Jul;33(3):155-60. doi: 10.4103/0971-5851.103142. Indian J Med Paediatr Oncol. 2012. PMID: 23248421 Free PMC article.
-
The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical - and futuristic - perspective.J Neurooncol. 2005 Dec;75(3):253-66. doi: 10.1007/s11060-005-6747-7. J Neurooncol. 2005. PMID: 16195805 Review.
-
Autologous hematopoietic stem cell transplantation for high-risk brain tumors in children.J Neurooncol. 2008 Feb;86(3):337-47. doi: 10.1007/s11060-007-9478-0. Epub 2007 Sep 29. J Neurooncol. 2008. PMID: 17906911 Free PMC article. Clinical Trial.
-
Extent of Tumor Resection and Survival in Pediatric Patients With High-Grade Gliomas: A Systematic Review and Meta-analysis.JAMA Netw Open. 2022 Aug 1;5(8):e2226551. doi: 10.1001/jamanetworkopen.2022.26551. JAMA Netw Open. 2022. PMID: 35972743 Free PMC article.
-
Pediatric high-grade glioma: current molecular landscape and therapeutic approaches.J Neurooncol. 2017 Sep;134(3):541-549. doi: 10.1007/s11060-017-2393-0. Epub 2017 Mar 29. J Neurooncol. 2017. PMID: 28357536 Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous